Stem Cell Therapy Study for Active Lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of lupus (SLE) with enough symptoms or lab findings to meet the standard criteria.
- You had a positive ANA or anti-dsDNA blood test in the last 6 months.
- Your kidneys are working at least moderately well (eGFR 30 or higher).
- You have been on a non-steroid lupus medication (like an immunosuppressant or antimalarial) for at least 12 weeks.
- Your lupus is currently active (SLEDAI-2K score of 6 or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This study looks at a type of immune cell in patients with active lupus. It may help doctors understand how lupus affects the immune system and could lead to better treatments.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.